


**Product Name** : VLS-1272  
**Cat. No.** : PC-23792  
**CAS No.** : 2914878-00-3  
**Molecular Formula** : C<sub>27</sub>H<sub>35</sub>N<sub>3</sub>O<sub>5</sub>S<sub>2</sub>  
**Molecular Weight** : 545.71  
**Target** : Kinesin  
**Solubility** : 10 mM in DMSO



CAS: 2914878-00-3

## Biological Activity

VLS-1272 is a potent, ATP non-competitive, orally bioavailable, and highly selective inhibitor of KIF18A ATPase activity with IC<sub>50</sub> of 41 nM and 8.8 nM for human and murine KIF18A (0.1 mM ATP), respectively.

VLS-1272 is an allosteric inhibitor of KIF18A.

VLS-1272 is selective for KIF18A over other kinesins, with no inhibition of KIF11/Eg5, KIF18B, or KIFC1 at 100 μM, and an IC<sub>50</sub> of 280 nM against KIF19.

VLS-1272 prevents cell proliferation to a greater degree in the CIN<sup>High</sup> (KIF2A over-expressing) vs. CIN<sup>Low</sup> (KIF2B over-expressing) MDA-MB-231 cell line pair.

VLS-1272 demonstrates that the specificity towards cancer cells with chromosome instability differentiates KIF18A inhibition from other clinically tested anti-mitotic drugs.

VLS-1272 also induced Caspase-3 cleavage in the sensitive OVCAR-3 cell line but not in the insensitive CAL51 cell line. VLS-1272 (30-60 mg/kg, BID, PO) exhibited robust dose-dependent inhibition of tumor growth in HCC15 and OVCAR-3 tumor models.

## References

Phillips AF, et al. Nat Commun. 2025 Jan 2;16(1):307.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com